Larisa Ryvo

Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: A basis for tumor-promoting interactions

Gali Soria, Neora Yaal‐Hahoshen, Elina Azenshtein et al. · Cytokine · 2008 · 90 citations

Concomitant Expression, Breast Oncology, Chemokines Rantes +12

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

István Láng, Thomas Brodowicz, Larisa Ryvo et al. · The Lancet Oncology · 2013 · 85 citations

Breast Oncology, Oncology, Medicine +8

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 83 citations · Full text

Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.

Sylvia Adams, Sherene Loi, Deborah Toppmeyer et al. · Journal of Clinical Oncology · 2017 · 72 citations

First-line Therapy, Breast Oncology, Cancer Management +18

Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry

Salomon M. Stemmer, Mariana Steiner, Shulamith Rizel et al. · npj Breast Cancer · 2017 · 68 citations · Full text